Bring up curcumin, berberine, quercetin, or medicinal-mushroom polysaccharides in an oncology context and you’ll hit the same qualifier: “still preclinical.” It can land like a verdict — as if the compound tried and didn’t make it.
It’s not a verdict; it’s a stage — and one worth understanding on its own terms. What’s easy to miss is how many of today’s standard cancer drugs stood exactly where these compounds stand now: a plant with a long history of use, then a lab curiosity, then years of testing. Some plants don’t survive that road. Several have — and they became chemotherapy.
This piece is about that lineage: why researchers keep returning to traditional-use plants as a starting point, why the pool is far larger than one famous rhizome, and why “traditional” and “preclinical” describe where a compound is, not where it will end up.
Traditional use is a lead, not a verdict
People noticed that certain plants and preparations changed pain, inflammation, infection, or wound healing long before anyone could isolate a molecule or name a pathway. That history doesn’t prove a remedy worked — and it certainly doesn’t prove it treats cancer. Traditional remedies were never tested against placebo, many conditions improve on their own, and a remedy can persist for reasons unrelated to pharmacology: availability, cultural weight, relative safety.
But there’s signal in the noise. A plant that repeatedly produced a noticeable effect across generations and independent traditions is likelier to contain something biologically active than one picked at random. Traditional use raises the prior probability worth investigating. It doesn’t settle the outcome — which is exactly why it’s a starting point, not a conclusion.
A whole field, not one rhizome
Curcumin, from turmeric, is the compound most people have heard of. But it sits inside a large, active list of traditional-use compounds in oncology-relevant research — among them berberine (studied for AMPK and cancer-cell metabolism), EGCG (green tea’s principal catechin, studied around angiogenesis and the proteasome), quercetin (a dietary flavonol studied for senolytic and antiproliferative activity), sulforaphane (from cruciferous vegetables, studied around NRF2 signaling), resveratrol (studied for sirtuin activation), and silymarin/silibinin from milk thistle. And many others — honokiol from magnolia bark, withaferin A from ashwagandha, betulinic acid from birch — sit in the same early research pool.
None has cleared the bar for cancer treatment. That’s not the point of the list. The point is that this is a field, not a single case study — and fields with this much active investigation tend to yield a handful of genuine successes over time, even when most candidates don’t. That’s not wishful thinking; it’s how drug discovery has always worked.
The precedent: plants that made it all the way
Several drugs in active chemotherapy protocols today started precisely where curcumin and berberine are now.
- Paclitaxel (Taxol), from Pacific yew bark, moved through a National Cancer Institute plant-screening program to FDA approval and remains a backbone agent for breast, ovarian, and lung cancers.
- Vincristine and vinblastine, from Madagascar periwinkle — itself a traditional remedy before its alkaloids were identified — became foundational in leukemia and lymphoma.
- Irinotecan and topotecan, derived from camptothecin in the Chinese “happy tree,” trace back to a traditional-medicine plant and now feature in colorectal, lung, and ovarian regimens.
- Artemisinin, from sweet wormwood and centuries of traditional use for fever, became the frontline antimalarial after modern isolation — a different disease, the same pipeline, and now studied for anticancer activity in its own right.
Every one spent years — often decades — as an unproven compound first. That’s not a promise curcumin or berberine will follow. It’s proof the path exists, has been walked successfully more than once, and that “preclinical” marks a position in a known process, not a prediction of failure.
Why isolation — and why “poorly absorbed” isn’t the end
Isolating a single compound lets researchers ask clean questions: exact dose, tissue concentration, molecular target, metabolite identity — and how altering the structure changes the effect, the structure-activity relationships that guide medicinal chemistry. It’s how an interesting plant becomes something measurable and reproducible.
It’s also where the real problem-solving happens. Discovering that a compound is potent in a dish but poorly absorbed in the body isn’t a dead end — it’s a design brief. It tells chemists what to fix: a better formulation, an analog, a delivery system, a partner that improves absorption. Curcumin’s low bioavailability, well documented in preclinical work, has directly driven liposomal, nanoparticle, and phospholipid-complexed formulations built to close that gap. Researchers can even run a Phase 0 microdosing trial — a tiny, sub-therapeutic first-in-human study — purely to measure how a compound behaves in people before committing to a full one.
The plant is a system, not one ingredient
There’s a second reason researchers study the whole plant, not just the isolate: the parts interact. A whole Curcuma longa extract has outperformed its separated curcuminoids against several cancer-cell lines in the lab; turmeric’s three curcuminoids together have shown additive-to-modestly-synergistic effects the single molecules didn’t; and compounds like piperine (black pepper) and turmerones (turmeric oil) measurably change how curcumin is absorbed. None of this guarantees synergy survives digestion and human dosing — one human study found post-digestive solubility mattered far more than added turmeric oils — but it’s why “plant extract” and “isolated compound” aren’t interchangeable, and why the complexity is being studied, not dismissed.
Why multi-target activity is interesting now
Cancer doesn’t run on one pathway — tumors adapt across growth signaling, metabolism, inflammation, DNA repair, and cell-death resistance at once, so blocking a single target often just shifts the burden. That’s part of why compounds with modest, multi-pathway activity — polypharmacology, common among natural products — are drawing renewed interest alongside single-target drugs, especially for prevention, supportive care, and combinations. “Acts on many pathways” isn’t automatically a virtue (it can also mean nonspecific assay activity), but it’s a genuinely different kind of opportunity — and a big reason this area hasn’t slowed.
Where this leaves things
Traditional use doesn’t validate an oncology claim, and nothing here should be treated as a cancer treatment — the human evidence for these compounds remains preclinical or early-stage for oncology, and that matters for anyone making treatment decisions. But “preclinical” describes a well-worn stage of a process that has produced real drugs from real plants, more than once, across very different diseases. The compounds under investigation now are being tested by a field with a track record — one that turned yew bark, periwinkle, and a Chinese fever remedy into chemotherapy backbones. That’s reason enough for interest, without overstating where any single compound stands.
← All articles